返回今日信号

ABBV

NYQ
AbbVie Inc.
医疗保健 Drug Manufacturers - General United States 官网
$253.35
+4.2% 当日
AI选股 2 条

AI选股记录

次日看涨Top3 #2 评分 82 概率 60%

这个股票来自自动 AI 选股池。以后只要 CLI 写入新的 ticker,这里会自动生成个股页面,不需要手工补页面。

2026-06-27 · 历史验证
ABBV

公司官方FDA批准发生在盘后,叠加当日强势收盘与高成交量,适合作为次交易日观察标的;但RSI偏高且盘后略回落,排在第二。

风险提示:RSI约76.5,短线拥挤度较高,若盘后FDA消息被卖出,可能出现回撤。; 平均目标价仅略高于现价,短线空间需要依赖资金延续而不是估值重估。
该股票的历史 AI 入选记录
2026-06-27
次日看涨Top3 #2
ABBV
公司官方FDA批准发生在盘后,叠加当日强势收盘与高成交量,适合作为次交易日观察标的;但RSI偏高且盘后略回落,排在第二。
82
2026-06-26
次日看涨Top3 #2
艾伯维Skyrizi获FDA儿科适应症批准,股价放量收在52周高位
公司官方FDA批准发生在盘后,叠加当日强势收盘与高成交量,适合作为次交易日观察标的;但RSI偏高且盘后略回落,排在第二。
82
查看AI历史

基本信息

市值
$447.62B
市盈率 TTM
123.59
前瞻市盈率
15.55
股息率
273.00%
52周高点
$253.35
52周低点
$181.75
Beta
0.31
日均成交量
7.03M

成交结构

基于近 60 日量价数据观察资金强弱。

截至 2026-06-26
资金流强弱 MFI
78.4
偏多
Chaikin 资金流 CMF
+0.410
强净流入
量能变化
8.38x
异动暴量
空头持仓比
1.48%
极低

交易信号历史

按时间回看该股票被模型捕捉到的买点信号。

共 0 条

公司简介

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

员工数量 57,000 总部 North Chicago, United States

最新资讯

外部数据 Yahoo Finance MarketWatch Stock Analysis Seeking Alpha